ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1991

Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation

Siba Raychaudhuri1, Smriti Raychaudhuri2 and Heike Wulff3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, 2VA Medical Center, Sacramento, CA, 3UC Davis, Davis, CA

Meeting: ACR Convergence 2022

Keywords: Animal Model, Cell-signalling molecules, Collagen-Induced Arthritis, rheumatoid arthritis, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Treatment Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1. Given its regulatory role in effector memory T cells, Kv1.3 is likely to play a critical role in the pathogenesis of T cell mediated autoimmune arthritis such as in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Here using Kv1.3−/− mice we are reporting that functional Kv1.3 channels are critical for induction of collagen induced arthritis (CIA). The novelty of this project lies in dissecting out the functional significance of Kv1.3 channels as a key regulator for activation of CD4+ TEM cell in RA. This study has the potential to bring new molecular understandings for the disease process of RA and to provide new avenues for treatment.

Methods: Kv1.3−/− mice are on the C57BL/6 background so we used C57BL/6 mice to induce CIA (Arthritis Research & Therapy 2007,9:R113). Briefly, 100ug chicken collagen type II (CCII)+CFA was injected intradermally (i.d.) in proximal tail on day 0 and the second i.d. injection of 100ug CCII +IFA was given on day 21. CIA was induced in Kv1.3−/− mice and in C57BL/6 wild-type (WT) (n=10, each). Arthritis was evaluated by clinical scores (CS) (weekly); histopathological scores (HS) and PET imaging studies of the joints were done on the day 0 and before sacrificing the mice on day-60. T cells from the spleens of WT and Kv1.3 KO mice (n=5, each) were separated and activated with CCII and cultured for 3 days to determine T cell activation/proliferation.

Results: Kv1.3−/− mice did not develop arthritis; whereas. As expected in this model about 75% of the wild-type C57BL/6 mice had arthritis. Arthritic changes appeared around day 28 and lasted beyond day 60. Scores for arthritis (CS and HS) on day-60 was zero in the Kv1.3−/− mice. In WT mice the CS was 2.8 ±0.5 and the HS was 6.2±1.5 (p< .01). In the Figure 1, representative histological sections from ankle joints are shown for Kv1.3−/− and WT mice. Evidence of arthritis was further confirmed/quantified by micro-PET imaging.

We also observed that knocking out of Kv1.3 renders T cells resistant to activation. As Kv1.3−/− mice did not develop inflammatory arthritis (Fig 1) we hypothesized that the T cells in Kv1.3-/- mice will fail to get activated by CCII. We separated T cells from the spleens of WT and Kv1.3-/- mice on day 60 of CIA induction. Using MTT test and FACS studies we observed a marked proliferation of CD4+ T cells with CCII in the WT compared to the Kv1.3 KO (p< 0.01) (Fig 2); and in the WT mice activation with CCII induced increased CD4+TEM cell proliferative response and secretion of IFN–γ in splenocytes (Fig 3), while in the Kv1.3-/- mice it is clear that knocking out of Kv1.3 renders CD4+ TEM cells resistant to activation (Fig 2 and 3).

Conclusion: In the CIA model here we have demonstrated WT mice developed clinical/histopathological, immunological and radiological evidences of inflammatory arthritis whereas Kv1.3−/− mice did not. This substantiates a critical role of the Kv1.3, a K+ channel in the pathogenesis of T cell mediated autoimmune arthritis including RA. These results provide a platform to develop small molecule-based novel Kv1.3 antagonists (e.g., PAP-1) for treatment of RA.

Supporting image 1

Figure 1. Kv1.3−/− mice did not develop CIA: A, B, C. PET-CT imaging on Day 60. A. C57BL/6 (wild type, control) not treated with chicken collagen. B [C57BL/6 (Kv1.3-KO)] and C [60C57BL/6 (wild type)] treated with chicken collagen (CCII). The PET-CT imaging is showing clear polyarthritis on Day 60 in the C57BL/6 (wild type) in the joints marked with the white stars.
D, E, F. Histopathological section on day 60 from ankle joints clearly show marked by the black arrow the characteristic histological changes with pannus formation after induction of CIA in the wild mouse (F) whereas in the Kv1.3-KO (E) and in the in the wild type control (D) there was no inflammation or pannus formation following induction of CIA .

Supporting image 2

Figure 2. Bar diagram showing significant proliferation (% of divided cells) of splenic CD4+ T cells with PHA and chicken collagen type II (CII) by MTT test in the C57BL/6 wild mice compared to Kv1.3−/− mice (*p<.01). Results were expressed as Mean±SD. One-way ANOVA with Tukey multiple comparison test was used to determine statistical significance. Further by FACS studies (CFSE dilution test) we noticed CII induced marked proliferation of the CD4+ Memory T cells demonstrated by more generations of cells and an increased number of cells in each generation in the wild mice compared to the Kv1.3 KO (Figure 3).

Supporting image 3

Figure 3. In the wild type (WT) activation with CII induced proliferation and IFN- γ secretion in CD4+ TEM cells but not in in the CD8+ TEM cells; and in the Kv1.3-/- mice it is clear that knocking out of Kv1.3 renders CD4+ TEM cells resistant to activation.


Disclosures: S. Raychaudhuri, AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sun, UCB; S. Raychaudhuri, None; H. Wulff, None.

To cite this abstract in AMA style:

Raychaudhuri S, Raychaudhuri S, Wulff H. Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/mice-do-not-develop-cia-knocking-out-of-kv1-3-renders-cd4temcells-resistant-to-activation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mice-do-not-develop-cia-knocking-out-of-kv1-3-renders-cd4temcells-resistant-to-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology